Sources of interindividual variability

Methods in Molecular Biology

Volumn 1113, Issue , 2014, Pages 363-415

  Thummel, Kenneth E ^a   Lin, Yvonne S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Age; Disease; Gender; Interindividual variability; Pharmacogenetics; Pharmacogenomics; Pregnancy

Indexed keywords

ALCOHOL; AMITRIPTYLINE; CITALOPRAM; CLOPIDOGREL; CODEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIPRAMINE; ISONIAZID; MERCAPTOPURINE; METFORMIN; MORPHINE; NICOTINE; NORTRIPTYLINE; OMEPRAZOLE; OXYCODONE; PHENYTOIN; SUXAMETHONIUM; TACROLIMUS; THIOPURINE METHYLTRANSFERASE; TRIMIPRAMINE; VINCRISTINE; WARFARIN;

AGING; ARTICLE; CATALYSIS; CIRCADIAN RHYTHM; COPY NUMBER VARIATION; DIET; DISEASE ASSOCIATION; DNA HYBRIDIZATION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME MECHANISM; ENZYME STABILITY; ENZYME STRUCTURE, FUNCTION AND VARIABILITY; ENZYME SUBSTRATE COMPLEX; ENZYME SYNTHESIS; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; HUMAN; INDEL MUTATION; INFECTION; INFLAMMATION; KIDNEY DISEASE; LIVER DISEASE; NONHUMAN; NUCLEOTIDE REPEAT; ONTOGENY; PHARMACOGENETICS; POPULATION GENETICS; PREGNANCY; PRIORITY JOURNAL; PROTEIN FUNCTION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; DISEASE; ENZYMES; GENETIC VARIATION; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; SAFETY;

EID: 84934434958     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-758-7_17     Document Type: Article

References (332)

1. Guengerich FP (2007) Mechanisms of cytochrome P450 substrate oxidation: MiniReview. J Biochem Mol Toxicol 21(4):163-168
2. Yang X, Zhang B, Molony C et al (2010) Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res 20(8):1020-1036. doi:10. 1101/gr.103341.109
3. von Richter O, Burk O, Fromm MF et al (2004) Cytochrome P450 3A4 and Pglycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens. Clin Pharmacol Ther 75(3):172-183. doi:10.1016/j.clpt.2003.10.008
4. Daly AK (2012) Genetic polymorphisms affecting drug metabolism: Recent advances and clinical aspects. Adv Pharmacol 63:137-167. doi:10.1016/B978-0-12- 398339-8.00004-5
5. Sim SC, Kacevska M, Ingelman-Sundberg M (2013) Pharmacogenomics of drugmetabolizing enzymes: A recent update on clinical implications and endogenous effects. Pharmacogenomics J 13(1):1-11. doi:10. 1038/tpj.2012.45
6. Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138(1):103-141. doi:10.1016/j. pharmthera.2012.12.007
7. Crawford DC, Nickerson DA (2005) Definition and clinical importance of haplotypes. Annu Rev Med 56:303-320. doi:10.1146/annurev.med.56.082103.104540
8. Nebert DW, Zhang G, Vesell ES (2008) From human genetics and genomics to pharmacogenetics and pharmacogenomics: Past lessons, future directions. Drug Metab Rev 40(2):187-224. doi:10.1080/03602530801952864
9. Gaedigk A, Blum M, Gaedigk R et al (1991) Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 48(5):943-950
10. Daly AK (2003) Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 17(1):27-41
11. de Morais SM, Wilkinson GR, Blaisdell J et al (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269(22):15419-15422
12. Sachse C, Brockmoller J, Bauer S et al (1997) Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet 60(2):284-295
13. Soyama A, Saito Y, Komamura K et al (2002) Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab Pharmacokinet 17(4):374-377
14. De Morais SM,Wilkinson GR, Blaisdell J et al (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46(4):594-598
15. Ferguson RJ, De Morais SM, Benhamou S et al (1998) A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of Smephenytoin. J Pharmacol Exp Ther 284(1):356-361
16. Kuehl P, Zhang J, Lin Y et al (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4):383-391. doi:10.1038/86882
17. Lin YS, Dowling AL, Quigley SD et al (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62(1):162-172
18. Schirmer M, Toliat MR, Haberl M et al (2006) Genetic signature consistent with selection against the CYP3A41B allele in non-African populations. Pharmacogenet Genomics 16(1):59-71
19. Zanger UM, Klein K (2013) Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): Advances on polymorphisms, mechanisms, and clinical relevance. Front Genet 4:24. doi:10.3389/fgene.2013.00024
20. Gaedigk A, Jaime LK, Bertino JS Jr et al (2010) Identification of novel CYP2D7-2D6 hybrids: Non-functional and functional variants. Front Pharmacol 1:121. doi:10.3389/fphar.2010.00121
21. Smit P, van Schaik RH, van der Werf M et al (2005) A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab 90(9):5313-5316. doi:10.1210/jc.2005-0307
22. Goodarzi MO, Xu N, Azziz R (2008) Association of CYP3A71C and serum dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 93(7):2909-2912. doi:10.1210/jc. 2008-0403
23. Chai X, Zeng S, Xie W (2013) Nuclear receptors PXR and CAR: Implications for drug metabolism regulation, pharmacogenomics and beyond. Expert Opin Drug Metab Toxicol 9(3):253-266. doi:10.1517/17425255. 2013.754010
24. Waxman DJ, Holloway MG (2009) Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 76(2):215-228. doi:10.1124/mol.109. 056705
25. Nakajima M, Yokoi T, Mizutani M et al (1999) Genetic polymorphism in the 50-flanking region of human CYP1A2 gene: Effect on the CYP1A2 inducibility in humans. J Biochem 125(4):803-808
26. Zanger UM, Fischer J, Raimundo S et al (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11(7):573-585
27. Rebbeck TR, Jaffe JM, Walker AH et al (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90(16):1225-1229
28. Bosma PJ, Chowdhury JR, Bakker C et al (1995) The genetic basis of the reduced expression of bilirubin UDPglucuronosyltransferase 1 in Gilbert?s syndrome. N Engl J Med 333(18):1171-1175. doi:10.1056/NEJM199511023331802
29. Raijmakers MT, Jansen PL, Steegers EA et al (2000) Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol 33(3):348-351
30. Ritter JK, Kessler FK, Thompson MT et al (1999) Expression and inducibility of the human bilirubin UDPglucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: Evidence for both genetic and environmental influences. Hepatology 30(2):476-484. doi:10. 1002/hep.510300205
31. Lankisch TO, Vogel A, Eilermann S et al (2005) Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene. Mol Pharmacol 67(5):1732-1739. doi:10.1124/mol.104.007146
32. Dalen P, Dahl ML, Bernal Ruiz ML et al (1998) 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 63(4):444-452. doi:10.1016/S0009-9236 (98)90040-6
33. Gasche Y, Daali Y, Fathi M et al (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351(27):2827-2831. doi:10.1056/NEJMoa041888
34. Gaedigk A, Fuhr U, Johnson C et al (2010) CYP2D7-2D6 hybrid tandems: Identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics 11(1):43-53. doi:10. 2217/pgs.09.133
35. Chida M, Yokoi T, Fukui T et al (1999) Detection of three genetic polymorphisms in the 50-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 90(9):899-902
36. Sachse C, Brockmoller J, Bauer S et al (1999) Functional significance of a C ! A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47(4):445-449
37. McCarver DG, Byun R, Hines RN et al (1998) A genetic polymorphism in the regulatory sequences of human CYP2E1: Association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol 152(1):276-281. doi:10.1006/taap.1998. 8532
38. Sim SC, Edwards RJ, Boobis AR et al (2005) CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A71C allele. Pharmacogenet Genomics 15(9):625-631
39. Sim SC, Risinger C, Dahl ML et al (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79(1):103-113. doi:10.1016/j.clpt.2005. 10.002
40. Daly AK (2010) Pharmacogenetics and human genetic polymorphisms. Biochem J 429(3):435-449. doi:10.1042/BJ20100522
41. Rodriguez-Antona C, Sayi JG, Gustafsson LL et al (2005) Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 338(1):299-305. doi:10.1016/j.bbrc. 2005.09.020
42. Amirimani B, Ning B, Deitz AC et al (2003) Increased transcriptional activity of the CYP3A41B promoter variant. Environ Mol Mutagen 42(4):299-305. doi:10. 1002/em.10199
43. Lamba JK, Lin YS, Thummel K et al (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12(2):121-132
44. Westlind A, Lofberg L, Tindberg N et al (1999) Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 50-upstream regulatory region. Biochem Biophys Res Commun 259(1):201-205. doi:10.1006/bbrc.1999. 0752
45. Tai HL, Fessing MY, Bonten EJ et al (1999) Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: Mechanism for TPMT protein deficiency inherited by TPMT2, TPMT3A, TPMT3B or TPMT3C. Pharmacogenetics 9(5):641-650
46. Krynetski EY, Tai HL, Yates CR et al (1996) Genetic polymorphism of thiopurine Smethyltransferase: Clinical importance and molecular mechanisms. Pharmacogenetics 6(4):279-290
47. Johansson I, Oscarson M, Yue QY et al (1994) Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46(3):452-459
48. Lamba JK (2008) Pharmacogenetics of the constitutive androstane receptor. Pharmacogenomics 9(1):71-83. doi:10.2217/14622416.9.1.71
49. Okey AB, Boutros PC, Harper PA (2005) Polymorphisms of human nuclear receptors that control expression of drug-metabolizing enzymes. Pharmacogenet Genomics 15(6):371-379
50. Zhang B, Xie W, Krasowski MD (2008) PXR: A xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 9(11):1695-1709. doi:10.2217/14622416.9.11.1695
51. Cornelis MC, Monda KL, Yu K et al (2011) Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoS Genet 7(4):e1002033. doi:10. 1371/journal.pgen. 1002033
52. Josse AR, Da Costa LA, Campos H et al (2012) Associations between polymorphisms in the AHR and CYP1A1-CYP1A2 gene regions and habitual caffeine consumption. Am J Clin Nutr 96(3):665-671. doi:10. 3945/ajcn.112.038794
53. Ikeda S, Kurose K, Ozawa S et al (2003) Twenty-six novel single nucleotide polymorphisms and their frequencies of the NR1I3 (CAR) gene in a Japanese population. Drug Metab Pharmacokinet 18(6):413-418
54. Ikeda S, Kurose K, Jinno Het al (2005) Functional analysis of four naturally occurring variants of human constitutive androstane receptor. Mol Genet Metab 86(1-2):314-319. doi:10.1016/j.ymgme. 2005.05.011
55. Chang TK, Bandiera SM, Chen J (2003) Constitutive androstane receptor and pregnane X receptor gene expression in human liver: Interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metabol Dispos 31(1):7-10
56. Lamba V, Lamba J, Yasuda K et al (2003) Hepatic CYP2B6 expression: Gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307(3):906-922. doi:10.1124/jpet.103. 054866
57. Wyen C, Hendra H, Siccardi M et al (2011) Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother 66(9):2092-2098. doi:10.1093/jac/dkr272
58. Lamba J, Lamba V, Schuetz E (2005) Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 6(4):369-383
59. Jinno H, Tanaka-Kagawa T, Hanioka N et al (2004) Identification of novel alternative splice variants of human constitutive androstane receptor and characterization of their expression in the liver. Mol Pharmacol 65(3):496-502. doi:10.1124/mol.65.3.496
60. Auerbach SS, Stoner MA, Su S et al (2005) Retinoid X receptor-alpha- dependent transactivation by a naturally occurring structural variant of human constitutive androstane receptor (NR1I3). Mol Pharmacol 68(5):1239-1253. doi:10.1124/mol.105. 013417
61. DeKeyser JG, Laurenzana EM, Peterson EC et al (2011) Selective phthalate activation of naturally occurring human constitutive androstane receptor splice variants and the pregnane X receptor. Toxicol Sci 120(2):381-391. doi:10.1093/toxsci/kfq394
62. Svard J, Spiers JP, Mulcahy F et al (2010) Nuclear receptor-mediated induction of CYP450 by antiretrovirals: Functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. J Acquir Immune Defic Syndr 55(5):536-549. doi:10.1097/QAI. 0b013e3181f52f0c
63. Chung JY, Cho JY, Lim HS et al (2011) Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Drug Metabol Dispos 39(1):92-97. doi:10.1124/dmd.110. 035246
64. Siccardi M, D?Avolio A, Baietto L et al (2008) Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C ! T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis 47(9):1222-1225. doi:10.1086/592304
65. Uno Y, Sakamoto Y, Yoshida K et al (2003) Characterization of six base pair deletion in the putative HNF1-binding site of human PXR promoter. J Hum Genet 48(11):594-597. doi:10.1007/s10038-003-0076-5
66. Lin YS, Yasuda K, Assem M et al (2009) The major human pregnane X receptor (PXR) splice variant, PXR.2, exhibits significantly diminished ligand-activated transcriptional regulation. Drug Metabol Dispos 37(6):1295-1304. doi:10.1124/dmd.108. 025213
67. Dickmann LJ, Rettie AE, Kneller MB et al (2001) Identification and functional characterization of a new CYP2C9 variant (CYP2C95) expressed among African Americans. Mol Pharmacol 60(2):382-387
68. Farres J, Wang X, Takahashi K et al (1994) Effects of changing glutamate 487 to lysine in rat and human liver mitochondrial aldehyde dehydrogenase. A model to study human (Oriental type) class 2 aldehyde dehydrogenase. J Biol Chem 269(19):13854-13860
69. Kitagawa K, Kawamoto T, Kunugita N et al (2000) Aldehyde dehydrogenase (ALDH) 2 associates with oxidation of methoxyacetaldehyde; in vitro analysis with liver subcellular fraction derived from human and Aldh2 gene targeting mouse. FEBS Lett 476(3):306-311
70. Callaghan JT, Bergstrom RF, Ptak LR et al (1999) Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37(3):177-193
71. Kassahun K, Mattiuz E, Nyhart E Jr et al (1997) Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metabol Dispos 25(1):81-93
72. Haslemo T, Loryan I, Ueda N et al (2012) UGT1A43 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems. Clin Pharmacol Ther 92(2):221-227. doi:10.1038/clpt. 2012.46
73. Lalovic B, Kharasch E, Hoffer C et al (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites. Clin Pharmacol Ther 79(5):461-479. doi:10. 1016/j.clpt.2006.01.009
74. Samer CF, Daali Y, Wagner M et al (2010) The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 160(4):907-918. doi:10.1111/j.1476-5381.2010.00673.x
75. Kurose K, Sugiyama E, Saito Y (2012) Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: Implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet 27(1):9-54
76. McGraw J, Waller D (2012) Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol 8(3):371-382. doi:10.1517/17425255. 2012.657626
77. Solus JF, Arietta BJ, Harris JR et al (2004) Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5(7):895-931. doi:10.1517/14622416.5.7. 895
78. Zanger UM, Turpeinen M, Klein K et al (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392(6):1093-1108. doi:10.1007/s00216-008- 2291-6
79. Evans WE, Relling MV (1999) Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286(5439):487-491
80. Evans WE, Relling MV (2004) Moving towards individualized medicine with pharmacogenomics. Nature 429(6990):464-468. doi:10.1038/nature02626
81. Silas JH, McGourty JC, Lennard MS et al (1985) Polymorphic metabolism of metoprolol: Clinical studies. Eur J Clin Pharmacol 28(Suppl):85-88
82. Sauer JM, Ring BJ, Witcher JW (2005) Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 44(6):571-590
83. Yue QY, Zhong ZH, Tybring G et al (1998) Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 64(4):384-390. doi:10.1016/S0009-9236(98) 90069-8
84. Ismail R, Teh LK (2006) The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther 31(1):99-109. doi:10. 1111/j.1365-2710.2006.00699.x
85. Sauer JM, Ponsler GD, Mattiuz EL et al (2003) Disposition and metabolic fate of atomoxetine hydrochloride: The role of CYP2D6 in human disposition and metabolism. Drug Metabol Dispos 31(1):98-107
86. Hicks JK, Swen JJ, Thorn CF et al (2013) Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants. Clin Pharmacol Ther 93:402-408. doi:10.1038/clpt.2013.2
87. Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II. Clin Pharmacokinet 48(12):761-804. doi:10.2165/11318070- 000000000-00000
88. Wernicke JF, Kratochvil CJ (2002) Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 63(Suppl 12):50-55
89. Crews KR, Gaedigk A, Dunnenberger HM et al (2012) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 91(2):321-326. doi:10.1038/clpt.2011.287
90. Kirchheiner J, Schmidt H, Tzvetkov M et al (2007) Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 7(4):257-265. doi:10.1038/sj. tpj.6500406
91. Brynne N, Dalen P, Alvan G et al (1998) Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther 63(5):529-539. doi:10.1016/S0009-9236(98)90104-7
92. Eap CB, Bondolfi G, Zullino D et al (2001) Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol 21(3):330-334
93. Lohmann PL, Rao ML, Ludwig M et al (2001) Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients. Eur J Clin Pharmacol 57(4):289-295
94. Sindrup SH, Brosen K, Gram LF et al (1992) The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 51(3):278-287
95. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52(4):349-355
96. Furuta T, Shirai N, Sugimoto M et al (2005) Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitorbased therapies. Drug Metab Pharmacokinet 20(3):153-167
97. Furuta T, Ohashi K, Kamata T et al (1998) Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129(12):1027-1030
98. Wan J, Xia H, He N et al (1996) The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. Br J Clin Pharmacol 42(4):471-474
99. Kirchheiner J, Nickchen K, Bauer M et al (2004) Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9(5):442-473. doi:10.1038/sj.mp.4001494
100. Kerb R, Fux R, Morike K et al (2009) Pharmacogenetics of antimalarial drugs: Effect on metabolism and transport. Lancet Infect Dis 9(12):760-774. doi:10.1016/S1473-3099 (09)70320-2
101. Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360(4):354-362. doi:10.1056/ NEJMoa0809171
102. Shuldiner AR, O?Connell JR, Bliden KP et al (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8):849-857. doi:10.1001/jama. 2009.1232
103. Sanford JC, Guo Y, Sadee W et al (2013) Regulatory polymorphisms in CYP2C19 affecting hepatic expression. Drug Metabol Drug Interact 28(1):23-30. doi:10.1515/dmdi-2012-0038
104. Li Y, Tang HL, Hu YF et al (2012) The gainof-function variant allele CYP2C1917: A double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. JTH 10(2):199-206. doi:10.1111/j.1538-7836.2011. 04570.x
105. Scott SA, Sangkuhl K, Stein CM et al (2013) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94:317-323. doi:10.1038/clpt.2013.105
106. Scordo MG, Pengo V, Spina E et al (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72(6):702-710. doi:10.1067/mcp. 2002.129321
107. Klein TE, Altman RB, Eriksson N et al (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360(8):753-764. doi:10.1056/NEJMoa0809329
108. Veenstra DL, Blough DK, Higashi MK et al (2005) CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 77(5):353-364. doi:10.1016/j.clpt. 2005.01.019
109. Higashi MK, Veenstra DL, Kondo LM et al (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13):1690-1698
110. Aynacioglu AS, Brockmoller J, Bauer S et al (1999) Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 48(3):409-415
111. Odani A, Hashimoto Y, Otsuki Y et al (1997) Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 62(3):287-292. doi:10.1016/S0009- 9236(97)90031-X
112. Shon JH, Yoon YR, Kim KA et al (2002) Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 12(2):111-119
113. Sullivan-Klose TH, Ghanayem BI, Bell DA et al (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6(4):341-349
114. Kidd RS, Straughn AB, Meyer MC et al (1999) Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C93 allele. Pharmacogenetics 9(1):71-80
115. Kirchheiner J, Roots I, Goldammer M et al (2005) Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: Clinical relevance. Clin Pharmacokinet 44(12):1209-1225
116. McCrea JB, Cribb A, Rushmore T et al (1999) Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin Pharmacol Ther 65(3):348-352. doi:10.1016/S0009-9236( 99)70114-1
117. Sekino K, Kubota T, Okada Y et al (2003) Effect of the single CYP2C93 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 59(8-9):589-592. doi:10.1007/s00228-003-0664-5
118. Daly AK (2010) Genome-wide association studies in pharmacogenomics. Nat Rev Genet 11(4):241-246. doi:10.1038/nrg2751
119. Haufroid V, Mourad M, Van Kerckhove V et al (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14(3):147-154
120. Hesselink DA, van Schaik RH, van der Heiden IP et al (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74(3):245-254. doi:10. 1016/S0009-9236(03)00168-1
121. MacPhee IA, Fredericks S, Tai T et al (2004) The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 4(6):914-919. doi:10.1111/j. 1600-6143.2004.00435.x
122. Thervet E, Anglicheau D, King B et al (2003) Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76(8):1233-1235. doi:10.1097/01.TP. 0000090753.99170.89
123. Macphee IA (2010) Use of pharmacogenetics to optimize immunosuppressive therapy. Ther Drug Monit 32(3):261-264. doi:10.1097/FTD.0b013e3181dca995
124. Zheng S, Tasnif Y, Hebert MF et al (2012) Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition. Clin Pharmacol Ther 92(6):737-745. doi:10.1038/clpt. 2012.175
125. Dennison JB, Jones DR, Renbarger JL et al (2007) Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 321(2):553-563. doi:10.1124/jpet.106. 118471
126. Dennison JB, Mohutsky MA, Barbuch RJ et al (2008) Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes. J Pharmacol Exp Ther 327(1):248-257. doi:10.1124/jpet.108.139998
127. Egbelakin A, Ferguson MJ, MacGill EA et al (2011) Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 56(3):361-367. doi:10.1002/pbc.22845
128. Floyd MD, Gervasini G, Masica AL et al (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European-and African-American men and women. Pharmacogenetics 13(10):595-606. doi:10.1097/01.fpc. 0000054118.14659.48
129. Goh BC, Lee SC, Wang LZ et al (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20(17):3683-3690
130. Shih PS, Huang JD (2002) Pharmacokinetics of midazolam and 10-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metabol Dispos 30(12):1491-1496
131. Wong M, Balleine RL, Collins M et al (2004) CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 75(6):529-538. doi:10. 1016/j.clpt.2004.02.005
132. Yu KS, Cho JY, Jang IJ et al (2004) Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 76(2):104-112. doi:10.1016/j.clpt. 2004.03.009
133. Zhang W, Chang YZ, Kan QC et al (2010) CYP3A41G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. Eur J Clin Pharmacol 66(1):61-66. doi:10.1007/s00228-009-0726-4
134. Miura M, Satoh S, Kagaya H et al (2011) Impact of the CYP3A41G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics 12(7):977-984. doi:10.2217/pgs.11.33
135. Wang D, Guo Y, Wrighton SA et al (2011) Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 11(4):274-286. doi:10.1038/tpj.2010.28
136. Elens L, Bouamar R, Hesselink DA et al (2011) A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 57(11):1574-1583. doi:10. 1373/clinchem.2011.165613
137. Elens L, Nieuweboer A, Clarke SJ et al (2013) CYP3A4 intron 6 C T SNP (CYP3A422) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics 14(2):137-149. doi:10.2217/pgs.12.202
138. de Wildt SN, Kearns GL, Leeder JS et al (1999) Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 36(6):439-452
139. Paoluzzi L, Singh AS, Price DK et al (2004) Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 44(8):854-860. doi:10.1177/0091270004267159
140. Innocenti F, Undevia SD, Iyer L et al (2004) Genetic variants in the UDPglucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22(8):1382-1388. doi:10.1200/JCO.2004.07.173
141. Ando Y, Saka H, Ando M et al (2000) Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 60(24):6921-6926
142. Iyer L, Das S, Janisch L et al (2002) UGT1A128 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2(1):43-47
143. Marcuello E, Altes A, Menoyo A et al (2004) UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91(4):678-682. doi:10.1038/sj.bjc.6602042
144. Innocenti F, Kroetz DL, Schuetz E et al (2009) Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 27(16):2604-2614. doi:10.1200/JCO. 2008.20.6300
145. Carlini LE, Meropol NJ, Bever J et al (2005) UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11(3):1226-1236
146. Ehmer U, Vogel A, Schutte JK et al (2004) Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDPglucuronosyltransferase UGT1A4. Hepatology 39(4):970-977. doi:10.1002/hep.20131
147. Zhou J, Argikar UA, Remmel RP (2011) Functional analysis of UGT1A4(P24T) and UGT1A4(L48V) variant enzymes. Pharmacogenomics 12(12):1671-1679. doi:10. 2217/pgs.11.105
148. Erickson-Ridout KK, Zhu J, Lazarus P (2011) Olanzapine metabolism and the significance of UGT1A448Vand UGT2B1067Y variants. Pharmacogenet Genomics 21(9):539-551. doi:10.1097/FPC. 0b013e328348c76b
149. Gulcebi MI, Ozkaynakci A, Goren MZ et al (2011) The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res 95(1-2):1-8. doi:10.1016/j.eplepsyres. 2011.01.016
150. Evans WE (2004) Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 26(2):186-191
151. Crabb DW, Edenberg HJ, Bosron WF et al (1989) Genotypes for aldehyde dehydrogenase deficiency and alcohol sensitivity. The inactive ALDH2(2) allele is dominant. J Clin Invest 83(1):314-316. doi:10.1172/JCI113875
152. Xiao Q, Weiner H, Johnston T et al (1995) The aldehyde dehydrogenase ALDH22 allele exhibits dominance over ALDH21 in transduced HeLa cells. J Clin Invest 96(5):2180-2186. doi:10.1172/JCI118272
153. Mizoi Y, Yamamoto K, Ueno Y et al (1994) Involvement of genetic polymorphism of alcohol and aldehyde dehydrogenases in individual variation of alcohol metabolism. Alcohol Alcohol 29(6):707-710
154. Wall TL (2005) Genetic associations of alcohol and aldehyde dehydrogenase with alcohol dependence and their mechanisms of action. Ther Drug Monit 27(6):700-703
155. van Kuilenburg AB (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40(7):939-950. doi:10.1016/j.ejca.2003. 12.004
156. Anderson GD (2005) Pregnancy-induced changes in pharmacokinetics: A mechanisticbased approach. Clin Pharmacokinet 44(10):989-1008
157. Hines RN (2008) The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 118(2):250-267. doi:10.1016/j. pharmthera.2008.02.005
158. Verbeeck RK, Musuamba FT (2009) Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 65(8):757-773. doi:10.1007/s00228-009-0678-8
159. Villeneuve JP, Pichette V (2004) Cytochrome P450 and liver diseases. Curr Drug Metab 5(3):273-282
160. Brockmoller J, Thomsen T, Wittstock M et al (2005) Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): Characterization by dynamic liver function tests. Clin Pharmacol Ther 77(6):529-541. doi:10. 1016/j.clpt.2005.02.003
161. Zhang Y, Zhang L, Abraham S et al (2009) Assessment of the impact of renal impairment on systemic exposure of new molecular entities: Evaluation of recent new drug applications. Clin Pharmacol Ther 85(3):305-311. doi:10.1038/clpt.2008.208
162. Huang YS, Lee SD, Deng JF et al (1993) Measuring lidocaine metabolite-monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 19(1):140-147
163. Shiffman ML, Luketic VA, Sanyal AJ et al (1994) Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. Hepatology 19(4):933-940
164. Molino G, Cavanna A, Avagnina P et al (1987) Hepatic clearance of D-sorbitol. Noninvasive test for evaluating functional liver plasma flow. Dig Dis Sci 32(7):753-758
165. Zeeh J, Lange H, Bosch J et al (1988) Steadystate extrarenal sorbitol clearance as a measure of hepatic plasma flow. Gastroenterology 95(3):749-759
166. Fazakas J, Mandli T, Ther G et al (2006) Evaluation of liver function for hepatic resection. Transplant Proc 38(3):798-800. doi:10. 1016/j.transproceed. 2006.01.048
167. Lorf T, Schnitzbauer AA, Schaefers SK et al (2008) Prognostic value of the monoethylglycinexylidide (MEGX)-test prior to liver resection. Hepatogastroenterology 55(82-83):539-543
168. George J, Liddle C, Murray M et al (1995) Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol 49(7):873-881
169. George J, Murray M, Byth K et al (1995) Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 21(1):120-128
170. Frye RF, Zgheib NK, Matzke GR et al (2006) Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther 80(3):235-245. doi:10. 1016/j.clpt.2006.05.006
171. Hatorp V, Walther KH, Christensen MS et al (2000) Single-dose pharmacokinetics of repaglinide in subjects with chronic liver disease. J Clin Pharmacol 40(2):142-152
172. Adedoyin A, Arns PA, Richards WO et al (1998) Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther 64(1):8-17. doi:10.1016/S0009-9236(98)90017-0
173. Pique JM, Feu F, de Prada G et al (2002) Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. Clin Pharmacokinet 41(12):999-1004
174. Sjovall H, Bjornsson E, Holmberg J et al (2002) Pharmacokinetic study of esomeprazole in patients with hepatic impairment. Eur J Gastroenterol Hepatol 14(5):491-496
175. Abdallah H, Jerling M (2005) Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustainedrelease tablets. J Clin Pharmacol 45(7):802-809. doi:10.1177/0091270005276739
176. Chalasani N, Gorski JC, Patel NH et al (2001) Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shunts. Hepatology 34(6):1103-1108. doi:10. 1053/jhep.2001.29306
177. Kleinbloesem CH, van Harten J, Wilson JP et al (1986) Nifedipine: Kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. Clin Pharmacol Ther 40(1):21-28
178. Nelson E (1964) Rate of metabolism of tolbutamide in test subjects with liver disease or with impaired renal function. Am J Med Sci 248:657-659
179. Chalon SA, Desager JP, Desante KA et al (2003) Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther 73(3):178-191. doi:10.1067/mcp.2003.25
180. Hoyumpa AM, Schenker S (1991) Is glucuronidation truly preserved in patients with liver disease Hepatology 13(4):786-795
181. Elekima OT, Mills CO, Ahmad A et al (2000) Reduced hepatic content of dehydroepiandrosterone sulphotransferase in chronic liver diseases. Liver 20(1):45-50
182. Hardwick RN, Ferreira DW, More VR et al (2013) Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. Drug Metabol Dispos 41(3):554-561. doi:10.1124/dmd.112. 048439
183. Morgan DJ, McLean AJ (1995) Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin Pharmacokinet 29(5):370-391
184. Palatini P, De Martin S, Pegoraro P et al (2008) Enzyme inhibition and induction in liver disease. Curr Clin Pharmacol 3(1):56-69
185. Lohr JW, Willsky GR, Acara MA (1998) Renal drug metabolism. Pharmacol Rev 50(1):107-141
186. Yeung CK, Lang DH, Thummel KE et al (2000) Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metabol Dispos 28(9):1107-1111
187. Zheng S, Tasnif Y, Hebert MF et al (2013) CYP3A5 gene variation influences cyclosporine a metabolite formation and renal cyclosporine disposition. Transplantation 95(6):821-827. doi:10.1097/TP. 0b013e31827e6ad9
188. Dai Y, Iwanaga K, Lin YS et al (2004) In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 68(9):1889-1902. doi:10.1016/j.bcp.2004. 07.012
189. Korashy HM, Elbekai RH, El-Kadi AO (2004) Effects of renal diseases on the regulation and expression of renal and hepatic drugmetabolizing enzymes: A review. Xenobiotica 34(1):1-29. doi:10.1080/00498250310001638460
190. Dowling TC, Briglia AE, Fink JC et al (2003) Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 73(5):427-434
191. Nolin TD, Frye RF, Le P et al (2009) ESRD impairs nonrenal clearance of fexofenadine but not midazolam. JASN 20(10):2269-2276. doi:10.1681/ASN. 2009010082
192. Elston AC, Bayliss MK, Park GR (1993) Effect of renal failure on drug metabolism by the liver. Br J Anaesth 71(2):282-290
193. Balant L, Francis RJ, Tozer TN et al (1980) Influence of renal failure on the hepatic clearance of bufuralol in man. J Pharmacokinet Biopharm 8(5):421-438
194. Gibson TP (1986) Renal disease and drug metabolism: An overview. Am J Kidney Dis 8(1):7-17
195. Touchette MA, Slaughter RL (1991) The effect of renal failure on hepatic drug clearance. Ann Pharmacother 25(11):1214-1224
196. Michaud J, Nolin TD, Naud J et al (2008) Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharmacol Sci 108(2):157-163
197. Szeto CC, Chow KM, Kwan BC et al (2006) Relation between number of prescribed medication and outcome in peritoneal dialysis patients. Clin Nephrol 66(4):256-262
198. Fletcher CV, Acosta EP, Strykowski JM (1994) Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Health 15(8):619-629
199. Harris RZ, Benet LZ, Schwartz JB (1995) Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50(2):222-239
200. Parkinson A, Mudra DR, Johnson C et al (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199(3):193-209. doi:10.1016/j.taap.2004. 01.010
201. Hunt CM, Westerkam WR, Stave GM (1992) Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44(2):275-283
202. Pollock BG (1997) Gender differences in psychotropic drug metabolism. Psychopharmacol Bull 33(2):235-241
203. Diczfalusy U, Miura J, Roh HK et al (2008) 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: Relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 18(3):201-208. doi:10.1097/FPC.0b013e3282f50ee9
204. Wolbold R, Klein K, Burk O et al (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38(4):978-988. doi:10.1053/jhep. 2003.50393
205. Hu ZY, Zhao YS (2010) Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: A meta-analysis. Drug Metabol Dispos 38(5):817-823. doi:10.1124/dmd.109. 031328
206. Chetty M, Mattison D, Rostami-Hodjegan A (2012) Sex differences in the clearance of CYP3A4 substrates: Exploring possible reasons for the substrate dependency and lack of consensus. Curr Drug Metab 13(6):778-786
207. Schuetz EG, Furuya KN, Schuetz JD (1995) Interindividual variation in expression of Pglycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275(2):1011-1018
208. Paine MF, Ludington SS, Chen ML et al (2005) Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression Drug Metabol Dispos 33(3):426-433. doi:10.1124/dmd.104. 002469
209. Relling MV, Lin JS, Ayers GD et al (1992) Racial and gender differences in Nacetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 52(6):643-658
210. Kim RB, O?Shea D (1995) Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 57(6):645-655. doi:10.1016/0009-9236(95) 90227-9
211. Bebia Z, Buch SC, Wilson JW et al (2004) Bioequivalence revisited: Influence of age and sex on CYP enzymes. Clin Pharmacol Ther 76(6):618-627. doi:10.1016/j.clpt.2004. 08.021
212. Aksoy IA, Sochorova V, Weinshilboum RM (1993) Human liver dehydroepiandrosterone sulfotransferase: Nature and extent of individual variation. Clin Pharmacol Ther 54(5):498-506
213. Brittelli A, De Santi C, Raunio H et al (1999) Interethnic and interindividual variabilities of platelet sulfotransferases activity in Italians and Finns. Eur J Clin Pharmacol 55(9):691-695
214. Marazziti D, Palego L, Rossi A et al (1998) Gender-related seasonality of human platelet phenolsulfotransferase activity. Neuropsychobiology 38(1):1-5
215. Boudikova B, Szumlanski C, Maidak B et al (1990) Human liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Ther 48(4):381-389
216. McLeod HL, Fang L, Luo X et al (1994) Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. J Pharmacol Exp Ther 270(1):26-29
217. McLeod HL, Lin JS, Scott EP et al (1994) Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 55(1):15-20
218. Court MH, Duan SX, von Moltke LL et al (2001) Interindividual variability in acetaminophen glucuronidation by human liver microsomes: Identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299(3):998-1006
219. Bock KW, Schrenk D, Forster A et al (1994) The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4(4):209-218
220. Miners JO, Attwood J, Birkett DJ (1983) Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol 16(5):503-509
221. Butera L, Feinfeld DA, Bhargava M (1990) Sex differences in the subunits of glutathione-S-transferase isoenzyme from rat and human kidney. Enzyme 43(4):175-182
222. Edelman A, Munar M, Elman MR et al (2012) Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women. Br J Clin Pharmacol 74(3):510-514. doi:10.1111/j.1365-2125.2012.04209.x
223. Palovaara S, Kivisto KT, Tapanainen P et al (2000) Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 10-hydroxylation. Br J Clin Pharmacol 50(4):333-337
224. Belle DJ, Callaghan JT, Gorski JC et al (2002) The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol 53(1):67-74
225. Schwartz JB (2003) The influence of sex on pharmacokinetics. Clin Pharmacokinet 42(2):107-121
226. Jennings TS, Nafziger AN, Davidson L et al (1993) Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism. J Lab Clin Med 122(2):208-216
227. Gorski JC, Vannaprasaht S, Hamman MA et al (2003) The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74(3):275-287. doi:10.1016/S0009-9236(03)00187-5
228. Hagg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51(2):169-173
229. Labbe L, Sirois C, Pilote S et al (2000) Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 10(5):425-438
230. Tamminga WJ, Wemer J, Oosterhuis B et al (1999) CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: Indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 55(3):177-184
231. Feghali MN, Mattison DR (2011) Clinical therapeutics in pregnancy. J Biomed Biotechnol 2011:783528. doi:10.1155/2011/783528
232. Tracy TS, Venkataramanan R, GloverDD et al (2005) Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol 192(2):633-639. doi:10.1016/j.ajog.2004. 08.030
233. Hebert MF, Easterling TR, Kirby B et al (2008) Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: A University of Washington specialized center of research study. Clin Pharmacol Ther 84(2):248-253. doi:10.1038/clpt.2008.1
234. Hogstedt S, Lindberg B, Peng DR et al (1985) Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther 37(6):688-692
235. Buchanan ML, Easterling TR, Carr DB et al (2009) Clonidine pharmacokinetics in pregnancy. Drug Metabol Dispos 37(4):702-705. doi:10.1124/dmd.108.024984
236. Ververs FF, Voorbij HA, Zwarts P et al (2009) Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin Pharmacokinet 48(10):677-683. doi:10.2165/11318050-000000000-00000
237. Hebert MF, Ma X, Naraharisetti SB et al (2009) Are we optimizing gestational diabetes treatment with glyburide The pharmacologic basis for better clinical practice. Clin Pharmacol Ther 85(6):607-614. doi:10. 1038/clpt.2009.5
238. Ohman I, Luef G, Tomson T (2008) Effects of pregnancy and contraception on lamotrigine disposition: New insights through analysis of lamotrigine metabolites. Seizure 17(2):199-202. doi:10.1016/j.seizure. 2007.11.017
239. Eyal S, Easterling TR, Carr D et al (2010) Pharmacokinetics of metformin during pregnancy. Drug Metabol Dispos 38(5):833-840. doi:10.1124/dmd.109.031245
240. Pasanen M, Pelkonen O (1994) The expression and environmental regulation of P450 enzymes in human placenta. Crit Rev Toxicol 24(3):211-229. doi:10.3109/10408449409021606
241. Rubinchik-Stern M, Eyal S (2012) Drug interactions at the human placenta: What is the evidence Front Pharmacol 3:126. doi:10.3389/fphar.2012.00126
242. Tomson T, Landmark CJ, Battino D (2013) Antiepileptic drug treatment in pregnancy: Changes in drug disposition and their clinical implications. Epilepsia 54(3):405-414. doi:10.1111/epi.12109
243. Wolff K, Boys A, Rostami-Hodjegan A et al (2005) Changes to methadone clearance during pregnancy. Eur J Clin Pharmacol 61(10):763-768. doi:10.1007/s00228-005-0035-5
244. van Heeswijk RP, Khaliq Y, Gallicano KD et al (2004) The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther 76(6):588-597. doi:10. 1016/j.clpt.2004.08.011
245. Jeong H (2010) Altered drug metabolism during pregnancy: Hormonal regulation of drug-metabolizing enzymes. Expert Opin Drug Metab Toxicol 6(6):689-699. doi:10. 1517/17425251003677755
246. Hines RN (2007) Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol 21(4):169-175
247. Stevens JC, Hines RN, Gu C et al (2003) Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 307(2):573-582. doi:10.1124/jpet.103.054841
248. Johnsrud EK, Koukouritaki SB, Divakaran K et al (2003) Human hepatic CYP2E1 expression during development. J Pharmacol Exp Ther 307(1):402-407. doi:10.1124/jpet. 102.053124
249. Treluyer JM, Jacqz-Aigrain E, Alvarez F et al (1991) Expression of CYP2D6 in developing human liver. Eur J Biochem 202(2):583-588
250. Blake MJ, Gaedigk A, Pearce RE et al (2007) Ontogeny of dextromethorphan O-and Ndemethylation in the first year of life. Clin Pharmacol Ther 81(4):510-516. doi:10. 1038/sj.clpt.6100101
251. Koukouritaki SB, Manro JR, Marsh SA et al (2004) Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 308(3):965-974. doi:10.1124/jpet.103.060137
252. Sonnier M, Cresteil T (1998) Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 251(3):893-898
253. Tateishi T, Nakura H, Asoh M et al (1997) A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci 61(26):2567-2574
254. Koukouritaki SB, Simpson P, Yeung CK et al (2002) Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res 51(2):236-243. doi:10.1203/00006450-200202000-00018
255. Smith M, Hopkinson DA, Harris H (1971) Developmental changes and polymorphism in human alcohol dehydrogenase. Ann Hum Genet 34(3):251-271
256. Krekels EH, Danhof M, Tibboel D et al (2012) Ontogeny of hepatic glucuronidation; methods and results. Curr Drug Metab 13(6):728-743
257. Blake MJ, Abdel-Rahman SM, Pearce RE et al (2006) Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr Res 60(6):717-723. doi:10.1203/01.pdr. 0000245909.74166.00
258. Battino D, Estienne M, Avanzini G (1995) Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin Pharmacokinet 29(5):341-369
259. Witcher JW, Long A, Smith B et al (2003) Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 13(1):53-63. doi:10.1089/104454603321666199
260. Wynne HA, Cope LH, Mutch E et al (1989) The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 9(2):297-301
261. Hermann R, Ferron GM, Erb K et al (2003) Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther 73(1):61-70. doi:10.1067/mcp. 2003.12
262. Sonne J, Loft S, Dossing M et al (1991) Single dose pharmacokinetics and pharmacodynamics of oral oxazepam in very elderly institutionalised subjects. Br J Clin Pharmacol 31(6):719-722
263. Miners JO, Penhall R, Robson RA et al (1988) Comparison of paracetamol metabolism in young adult and elderly males. Eur J Clin Pharmacol 35(2):157-160
264. Qato DM, Alexander GC, Conti RM et al (2008) Use of prescription and over-thecounter medications and dietary supplements among older adults in the United States. JAMA 300(24):2867-2878. doi:10.1001/jama.2008.892
265. Anderson KE, McCleery RB, Vesell ES et al (1991) Diet and cimetidine induce comparable changes in theophylline metabolism in normal subjects. Hepatology 13(5):941-946
266. Tinkelman DG, Edelman L, Decouto J et al (1985) The effect of diet on the metabolism of long acting theophylline. Ann Allergy 54(4):280-283
267. Lampe JW, King IB, Li S et al (2000) Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: Changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis 21(6):1157-1162
268. Sinha R, Rothman N, Brown ED et al (1994) Pan-fried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans. Cancer Res 54(23):6154-6159
269. Homeida M, Karrar ZA, Roberts CJ (1979) Drug metabolism in malnourished children: A study with antipyrine. Arch Dis Child 54(4):299-302
270. Ohlman S, Lindholm A, Hagglund H et al (1993) On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. Eur J Clin Pharmacol 44(3):265-269
271. Klotz U, Ziegler G (1982) Physiologic and temporal variation in hepatic elimination of midazolam. Clin Pharmacol Ther 32(1):107-112
272. Ohno M, Yamaguchi I, Ito T et al (2000) Circadian variation of the urinary 6betahydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity. Eur J Clin Pharmacol 55(11-12):861-865
273. Lindh JD, Andersson ML, Eliasson E et al (2011) Seasonal variation in blood drug concentrations and a potential relationship to vitamin D. Drug Metabol Dispos 39(5):933-937. doi:10.1124/dmd.111. 038125
274. Thirumaran RK, Lamba JK, Kim RB et al (2012) Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochem Pharmacol 84(1):104-112. doi:10. 1016/j.bcp.2012.03.017
275. Aitken AE, Richardson TA, Morgan ET (2006) Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46:123-149. doi:10.1146/annurev.pharmtox.46.120604. 141059
276. Morgan ET (2009) Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 85(4):434-438. doi:10.1038/clpt.2008.302
277. Morgan ET, Goralski KB, Piquette-Miller M et al (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metabol Dispos 36(2):205-216. doi:10.1124/dmd.107. 018747
278. Satarug S, Lang MA, Yongvanit P et al (1996) Induction of cytochrome P450 2A6 expression in humans by the carcinogenic parasite infection, opisthorchiasis viverrini. Cancer Epidemiol Biomark Pre 5(10):795-800
279. Treluyer JM, Benech H, Colin I et al (2000) Ontogenesis of CYP2C-dependent arachidonic acid metabolism in the human liver: Relationship with sudden infant death syndrome. Pediatr Res 47(5):677-683
280. Treluyer JM, Cheron G, Sonnier M et al (1996) Cytochrome P-450 expression in sudden infant death syndrome. Biochem Pharmacol 52(3):497-504
281. Jones AE, Brown KC,Werner RE et al (2010) Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol 66(5):475-485. doi:10.1007/s00228-009-0777-6
282. Jetter A, Fatkenheuer G, Frank D et al (2010) Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients Antivir Ther 15(7):975-983. doi:10.3851/IMP1648
283. Chang KC, Bell TD, Lauer BA et al (1978) Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1(8074):1132-1133
284. Kraemer MJ, Furukawa CT, Koup JR et al (1982) Altered theophylline clearance during an influenza B outbreak. Pediatrics 69(4):476-480
285. Carcillo JA (2005) Reducing the global burden of sepsis in infants and children: A clinical practice research agenda. Pediatr Crit Care Med 6(3 Suppl):S157-S164. doi:10. 1097/01.PCC.0000161574.36857.CA
286. Haas CE, Kaufman DC, Jones CE et al (2003) Cytochrome P450 3A4 activity after surgical stress. Crit Care Med 31(5):1338-1346. doi:10.1097/01.CCM. 0000063040.24541.49
287. Lee CM, Pohl J, Morgan ET (2009) Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures. Drug Metabol Dispos 37(4):865-872. doi:10.1124/dmd.108. 026187
288. Chen YL, Le Vraux V, Leneveu A et al (1994) Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 55(6):649-660
289. Schmitt C, Kuhn B, Zhang X et al (2011) Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther 89(5):735-740. doi:10.1038/clpt.2011.35
290. Dickmann LJ, Patel SK, Rock DA et al (2011) Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drugmetabolizing enzymes in human hepatocyte culture. Drug Metabol Dispos 39(8):1415-1422. doi:10.1124/dmd.111. 038679
291. Brennan BJ, Xu ZX, Grippo JF (2013) Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity. Br J Clin Pharmacol 75(2):497-506. doi:10.1111/j. 1365-2125.2012.04373.x
292. Huang SM, Temple R (2008) Is this the drug or dose for you Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther 84(3):287-294. doi:10. 1038/clpt.2008.144
293. Guengerich FP, Turvy CG (1991) Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 256(3):1189-1194
294. Sotaniemi EA, Rautio A, Backstrom M et al (1995) CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Br J Clin Pharmacol 39(1):71-76
295. Furlan V, Demirdjian S, Bourdon O et al (1999) Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. J Pharmacol Exp Ther 289(2):1169-1175
296. Marcellin P, de Bony F, Garret C et al (2001) Influence of cirrhosis on lamotrigine pharmacokinetics. Br J Clin Pharmacol 51(5):410-414
297. Marbury TC, Ruckle JL, Hatorp V et al (2000) Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 67(1):7-15. doi:10.1067/mcp. 2000.103973
298. Chapelsky MC, Thompson-Culkin K, Miller AK et al (2003) Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 43(3):252-259
299. Thompson-Culkin K, Zussman B, Miller AK et al (2002) Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. J Int Med Res 30(4):391-399
300. Aramwit P, Supasyndh O, Sriboonruang T (2008) Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients. J Clin Pharm Ther 33(6):685-690. doi:10.1111/j.1365-2710. 2008.00967.x
301. Dreisbach AW, Japa S, Gebrekal AB et al (2003) Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther 73(5):475-477
302. Vinik HR, Reves JG, Greenblatt DJ et al (1983) The pharmacokinetics of midazolam in chronic renal failure patients. Anesthesiology 59(5):390-394
303. Muirhead GJ, Rance DJ, Walker DK et al (2002) Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br J Clin Pharmacol 53(Suppl 1):13S-20S
304. Singlas E, Pioger JC, Taburet AM et al (1989) Zidovudine disposition in patients with severe renal impairment: Influence of hemodialysis. Clin Pharmacol Ther 46(2):190-197
305. Kim YG, Shin JG, Shin SG et al (1993) Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther 54(6):612-620
306. Brazier JL, Ritter J, Berland M et al (1983) Pharmacokinetics of caffeine during and after pregnancy. Dev Pharmacol Ther 6(5):315-322
307. Parsons WD, Pelletier JG (1982) Delayed elimination of caffeine by women in the last 2 weeks of pregnancy. Can Med Assoc J 127(5):377-380
308. Carter BL, Driscoll CE, Smith GD (1986) Theophylline clearance during pregnancy. Obstet Gynecol 68(4):555-559
309. Gardner MJ, Schatz M, Cousins L et al (1987) Longitudinal effects of pregnancy on the pharmacokinetics of theophylline. Eur J Clin Pharmacol 32(3):289-295
310. Wright LN, Thorp JM Jr, Kuller JA et al (1997) Transdermal nicotine replacement in pregnancy: Maternal pharmacokinetics and fetal effects. Am J Obstet Gynecol 176(5):1090-1094
311. Cressey TR, Stek A, Capparelli E et al (2012) Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr 59(3):245-252. doi:10.1097/QAI. 0b013e31823ff052
312. Dickinson RG, Hooper WD, Wood B et al (1989) The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin. Br J Clin Pharmacol 28(1):17-27
313. Tomson T, Lindbom U, Ekqvist B et al (1994) Disposition of carbamazepine and phenytoin in pregnancy. Epilepsia 35(1):131-135
314. McGready R, Stepniewska K, Edstein MD et al (2003) The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur J Clin Pharmacol 59(7):545-552. doi:10.1007/s00228-003-0652-9
315. McGready R, Stepniewska K, Seaton E et al (2003) Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol 59(7):553-557. doi:10.1007/s00228-003-0651-x
316. Wadelius M, Darj E, Frenne G et al (1997) Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 62(4):400-407. doi:10. 1016/S0009-9236(97)90118-1
317. Watts DH, Brown ZA, Tartaglione T et al (1991) Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis 163(2):226-232
318. O?Sullivan MJ, Boyer PJ, Scott GB et al (1993) The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol 168(5):1510-1516
319. Tsutsumi K, Kotegawa T, Matsuki S et al (2001) The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and Nacetyltransferase activities in humans. Clin Pharmacol Ther 70(2):121-125. doi:10. 1067/mcp.2001.116495
320. Cazeneuve C, Pons G, Rey E et al (1994) Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults. Br J Clin Pharmacol 37(5):405-412
321. Strolin Benedetti M, Whomsley R, Baltes EL (2005) Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 1(3):447-471. doi:10.1517/17425255.1.3. 447
322. Gu J, Su T, Chen Y et al (2000) Expression of biotransformation enzymes in human fetal olfactory mucosa: Potential roles in developmental toxicity. Toxicol Appl Pharmacol 165(2):158-162. doi:10.1006/taap.2000. 8923
323. Shimada T, Yamazaki H, Mimura M et al (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270(1):414-423
324. George J, Byth K, Farrell GC (1995) Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol 50(5):727-730
325. Vieira I, Sonnier M, Cresteil T (1996) Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur J Biochem 238(2):476-483
326. Kinirons MT, O?Mahony MS (2004) Drug metabolism and ageing. Br J Clin Pharmacol 57(5):540-544. doi:10.1111/j.1365-2125. 2004.02096.x
327. Lacroix D, Sonnier M, Moncion A et al (1997) Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 247(2):625-634
328. Onishi S, Kawade N, Itoh S et al (1979) Postnatal development of uridine diphosphate glucuronyltransferase activity towards bilirubin and 2-aminophenol in human liver. Biochem J 184(3):705-707
329. Strassburg CP, Strassburg A, Kneip S et al (2002) Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50(2):259-265
330. Duanmu Z, Weckle A, Koukouritaki SB et al (2006) Developmental expression of aryl, estrogen, and hydroxysteroid sulfotransferases in pre-and postnatal human liver. J Pharmacol Exp Ther 316(3):1310-1317. doi:10.1124/jpet.105.093633
331. Temellini A, Giuliani L, Pacifici GM (1991) Interindividual variability in the glucuronidation and sulphation of ethinyloestradiol in human liver. Br J Clin Pharmacol 31(6):661-664
332. Strange RC, Howie AF, Hume R et al (1989) The development expression of alpha-, muand pi-class glutathione S-transferases in human liver. Biochim Biophys Acta 993(2-3):186-190